This is our running summary of the Dupixent T-cell lymphoma litigation. We rewrite it each month. It was last checked on November 12, 2026.
T-Cell Lymphoma After Dupixent?
You may have a claim if all three are true:
- You were prescribed Dupixent (dupilumab), most often for eczema or asthma.
- You were later diagnosed with cutaneous T-cell lymphoma, including mycosis fungoides or Sézary syndrome, or another T-cell lymphoma.
- The diagnosis came after you started the drug.
All three? Call 866-837-1010 or send us a message. The review is free.
Where the Dupixent Lawsuit Stands in November 2026
| Item | Status |
|---|---|
| Federal cases | MDL 3180, District of New Jersey, Judge Zahid N. Quraishi |
| Created | June 4, 2026, with 15 cases and 7 tag-along actions |
| Cases pending | 40 on November 2, 2026 |
| Defendants | Sanofi and Regeneron |
| Claim | Failure to warn that Dupixent can cause or accelerate cutaneous T-cell lymphoma |
| Settlement | None |
| Label | No T-cell lymphoma warning; no recall |
What Has Happened Since the MDL Was Formed
- June 4, 2026: the federal panel created MDL 3180 in New Jersey. Plaintiffs had asked for the Northern District of Georgia, which then held more Dupixent cases than any other district.
- October 22: the court reportedly appointed the plaintiffs’ leadership.
- October 30: the parties filed proposed orders on case management, direct filing of new cases and depositions.
- November 2: plaintiff-side reports say Judge Quraishi entered a discovery schedule in two phases, starting with whether Dupixent can cause T-cell lymphoma, with plaintiff profile forms beginning December 18.
When Could the Dupixent Cases Settle?
Not for a long while. The litigation is five months old. Before anyone talks about money, the court has to decide whether the science supports the claim that Dupixent can cause T-cell lymphoma. That question comes first in the schedule, and a ruling for the companies could end most cases. Only after it, and usually after the first trials, do settlements become realistic.
Are There Dupixent Settlement Amounts?
No. Nothing has settled and nothing has been tried, so there is no figure to report. What would matter if the cases resolve: the type and stage of lymphoma, the treatment required, how long you took Dupixent before diagnosis, and whether a skin condition treated as eczema was lymphoma all along.
The Science in One Paragraph
A 2024 study in JAMA Dermatology of 19,612 patients found Dupixent users were about four times more likely to develop cutaneous T-cell lymphoma. FDA adverse event data reflected nearly 300 lymphoma reports by January 2026, 138 of them specific to this cancer. Those findings are the basis of the lawsuits; they are not proof in any one case. Our article Does Dupixent Cause Cancer? goes through the evidence and its limits.
What to Do Now
Do not stop a prescribed drug without talking to your doctor. If you were diagnosed with a T-cell lymphoma after taking Dupixent, keep your pharmacy and biopsy records and have your dates checked. Alabama and Georgia generally allow two years and Tennessee one. State pages: Alabama Dupixent lawsuit, Georgia Dupixent lawsuit and Tennessee Dupixent lawsuit.
Talk With a Dupixent Lawyer
Fob & Foster Personal Injury Lawyers review these claims at no charge. Call 866-837-1010 or send us a message. There is no fee unless we recover for you.
Frequently Asked Questions
What is the latest on the Dupixent lawsuit?
As of November 2026, 40 cases are pending in MDL 3180 in the District of New Jersey. Proposed case management orders were filed October 30, and plaintiff-side reports say the court has set a two-phase discovery schedule beginning with whether Dupixent can cause T-cell lymphoma.
Has the Dupixent lawsuit been settled?
No. No settlement has been announced, no case has been tried, and the litigation was consolidated only in June 2026.
What are Dupixent lawsuit settlement amounts?
There are none. No Dupixent lymphoma case has settled publicly or reached a verdict, so any amount quoted online is a projection.
Does the Dupixent label warn about lymphoma?
No. As of November 2026 the FDA-approved prescribing information does not mention T-cell lymphoma, and there has been no recall.
Fob James, IV
Fob James obtained a B.S., in software engineering from Auburn University and then continued his education by getting his J.D. from Vanderbilt University School of Law. After working for a large national firm for several years, Fob found that his passion was fighting for individuals who have been seriously injured or wronged by others. Fob believes that the jury is the great equalizer to the power and influence that large corporations have in society. Many of Fob’s cases are high profile and have been featured in, among others: Bloomberg News, PlanAdvisor, AL.com, PlanSponsor, National Law Review, and BusinessInsider. For his work in obtaining numerous multi-million dollar outcomes for his clients, Fob has been recognized by: National Trial Lawyers Top 100, SuperLawyers Rising Star (2020-2026), Birmingham Business Journal Who’s Who in Law (2023-2025), and TrustAnalytica – Top Personal Injury Lawyers in Alabama.